## Drug Status Report

## **Drug:** [<sup>123</sup>I]Ioflupane

**Drug Name Status**: Ioflupane (<sup>123</sup>I) is the proper name (INN).

**Chemical Name:** Methyl 8-(3-fluoropropyl)- $3\beta$ -(*p*-iodo-<sup>123</sup>I-phenyl)- $1\alpha$ , $5\alpha$ H-nortropane - $2\beta$ -carboxylate

**Other Names:** [1R-(exo,exo)]-8-(3-Fluoropropyl)-3[4-(iodo<sup>123</sup>I)phenyl]-8azabicyclo[3.2.1]octane-2-carboxylic acid methyl ester; N-(3-fluoropropyl)-2 $\beta$ -carboxymethoxy-3 $\beta$ -(4-<sup>123</sup>I-iodophenyl)nortropane); <sup>123</sup>I-FP-CIT; DaTSCAN

## **Chemical structure:**



Molecular Formula: C<sub>18</sub>H<sub>23</sub>F<sup>123</sup>INO<sub>2</sub>

Pharmacological class / Application: Radioactive imaging agent

## International status:

**US:** The substance is not listed specifically in the Schedules to the CSA and is not mentioned in the DEA website.

**United Nations:** The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

**Canadian Status:** [<sup>123</sup>I]Ioflupane is a radioactive imaging agent that was developed for molecular imaging studies of neurological conditions such as Parkinson's Disease<sup>1</sup>, Alzheimer's

<sup>&</sup>lt;sup>1</sup>Vlaar, AMM. *et al.* (2008) Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes, Eur. Neurol. **59**:258-266.

disease and dementia<sup>2</sup> and Creutzfeldt-Jakob disease<sup>3</sup>. The substance is a structural analogue of cocaine, synthesized from Nor- $\beta$ -CIT, and demonstrates specific binding to the dopamine transporters<sup>4</sup>.

Cocaine is currently listed as Sub-item 2 under Item 2 of Schedule I to the CDSA, under the heading "Coca (Erythroxylon), its preparations, derivatives, alkaloids and salts including:". A recent review of Nor- $\beta$ -CIT determined the substance to be controlled under Item 2 of Schedule I to the CDSA. While [<sup>123</sup>I]Ioflupane is mainly used for the purposes of diagnostic neurological imaging, ioflupane is derived from Nor- $\beta$ -CIT, which in turn is prepared directly from cocaine, and thus is considered to be included under Item 2(2) of Schedule I under the heading "Coca (Erythroxylon), its preparations, derivatives, alkaloids and salts, including:" Accordingly, the <sup>123</sup>I radioisotope of isoflupane would also be included under Item 2 of Schedule I to the CDSA.

Recommendation: [<sup>123</sup>I]Ioflupane is included in Item 2 of Schedule I to the CDSA and is a controlled substance.

March 19<sup>th</sup>, 2010.

<sup>&</sup>lt;sup>2</sup>Colloby, SJ. *et al.* (2008) A comparison of 99mTc-exametazime and <sup>123</sup>I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies, Int. Pscyhogeriatrics, **20**:1124-40.

<sup>&</sup>lt;sup>3</sup>Ragno, M. *et al.* (2009) Striatal [123I] FP-CIT SPECT demonstrates dopaminergic deficit of a sporadic case of Creutzfeldt-Jakob disease, Acta Neurlogica Scandinavica, **119**:131-134.

<sup>&</sup>lt;sup>4</sup>Neumeyer, JL. *et al.* (1994) N-ω-Fluoroalkyl analogues of (1R)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT): Radiotracers for Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging of Dopamine Transporters, J. Med. Chem. **37**:1558-1561.